VBIO Latest Press Releases

-- June 25, 2026 --

AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS PRNewswire 7:45 AM

-- June 11, 2026 --

Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures PRNewswire 7:45 AM

-- May 19, 2026 --

VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME PRNewswire 4:39 PM

-- May 14, 2026 --

Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR Platform PRNewswire 4:32 PM

VALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS PRNewswire 4:05 PM

-- May 11, 2026 --

Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026 PRNewswire 8:01 AM

-- May 5, 2026 --

VALION BIO RECEIVES FIRST FDA-PRECEDENT STUDY PROTOCOL FROM NIAID FOR ENTOLIMOD ; FEDERAL AGENCY TO FULLY FUND BLA-ENABLING IN VIVO PROGRAM AND CO-NAVIGATE FDA SUBMISSION PRNewswire 8:00 AM

-- May 4, 2026 --

Valion Bio Appoints Melinda Lackey as General Counsel PRNewswire 4:05 PM

-- April 28, 2026 --

VALION BIO BRIEFS PENTAGON LEADERSHIP ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME PRNewswire 8:01 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software